Apar Ganti, MD, University of Nebraska Medical Center

home / authors / apar-ganti,-md,-university-of-nebraska-medical-center

Articles

Q & A and Final Thoughts

Q & A and Final Thoughts

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Unmet Needs and Challenges in Treating R/R SCLC

Unmet Needs and Challenges in Treating R/R SCLC

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Role of Newer Agents in the Treatment & Patient Selection

Role of Newer Agents in the Treatment & Patient Selection

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Use of I/O Regimen in Relapsed/Refractory SCLC

Use of I/O Regimen in Relapsed/Refractory SCLC

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Advice on Toxicity Management for SCLC Therapy

Advice on Toxicity Management for SCLC Therapy

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Personal Approach in Treatment Compared to Clinical Trials

Personal Approach in Treatment Compared to Clinical Trials

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Recent Progress in the Treatment of SCLC

Recent Progress in the Treatment of SCLC

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Introduction and Identifying Predictive Biomarkers

Introduction and Identifying Predictive Biomarkers

Vivek Subbiah, MD, MD Anderson Cancer Center;Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital;Apar Ganti, MD, University of Nebraska Medical Center
August 20th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data